|
Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060 EISSN: 1678-8060
Vol. 89, Num. 2, 1994, pp. 297-298
|
Mem. Inst. Oswaldo Cruz, Rio de Janeiro, Vol. 89(2):
297-298, apr./jun. 1994
Report of the Meeting on Genetic Vaccines (Naked DNA/RNA) WHO
Geneva, May 17-18, 1994
Jose Luis Ramirez
Code Number: OC94059
Size of Files:
Text: 9.5K
No associated graphics files:
Grupo de Genetica Molecular, Centro de Biologia Celular, UCV, Apdo
47525, Caracas 1041-A, Venezuela
The idea of injecting naked DNA to get antigen production, and
trigger the immune response, was reborn after the experiments
conducted by Jon Wolff's Laboratory in the University of Wisconsin
at Madison, and was ably commented by Jon Cohen (1993), and Thoman
Braciale (1993). Several years ago, Benvenisty and Reshef (1986),
emitted the astonishing report that viral and cellular gene
promoters fused to the chloramphenicol acetyltransferase gene (CAT)
and the hepatitis B surface antigen (HBSA), when injected into liver
and spleen of newborn rats, would result in the expression of CAT
and HBSA. No other reports appeared until the Science 1990
paper by Wolf et al. (1990). Here, DNA and RNA expression vectors
containing genes for CAT, luciferase and beta-galactosidade injected
into mouse skeletal muscle in vivo, expressed proteins with
no requirement for special delivery systems. The key issue in this
new approach rests in the assumption that, when vaccination with
purified proteins or peptide is carried out, these molecules are
degraded by macrophage's endosomal cell system, and presented
afterwards at the surface for lymphocyte recognition. Live virus
vaccines are best, because the proteins are expressed inside the
cells and folded and presented efficiently at the cell's surface.
Thus, since in the DNA vaccines the proteins are properly expressed
and correctly presented by the muscle cells (from within) they
should resemble live vaccines. In order to review the current status
of the field, and discuss the latest developments in this new
approach to vaccination, the Global Programme for Vaccines (GPV),
the Special Programme for Research and Training in Tropical Diseases
(TDR), and the Global Programme on AIDS (GPA), jointly organized the
Genetic Vaccines Meeting.
The Meeting was divided into six parts: General issues, Vaccine
potential, DNA vaccines, RNA vaccines, Safety and regulatory issues,
and Specific vaccines. The speakers were leaders of the respective
fields. In the first section Professor Zinkernagel from the
University of Zurich, reviewed the basis of vaccination, covering
such subjects as antigen presentation, tolerance, memory and
immunogenetic capacity in different systems. This talk was
enlightening since it addressed the many questions raised by this
new technology, its advantages and potential dangers. I will refer
to the few critical issues I derived from this and following talks.
Most of the experimentation has been carried out injecting muscle
(so far the best target), shooting the skin and or spraying the
nasal mucose. As the immunology dogma goes, miocytes or keratocytes
are not considered to be typical antigen- presenting cells.
Therefore, either these cells are revealing unknown capacities, or a
minor fraction of other cells, such as skin Largerham cells, are
responsible for this presentation. In the latter case, the large
amounts of DNA injected are justified by the scarcity of target
cells. Also, since we do not yet know how to calibrate the dose, and
how to focus on target cells, how can we control antigen
presentation, and avoid the generation of tolerance at suboptimum
doses? This is particularly hot issue, since a large part of the
vaccination programs are focussed on babies, whose immunological
systems may not be fully developed.
An intriguing, yet unexplained fact, is that DNA/RNA vaccines
activate mostly cytotoxic cells (cytotoxic T lymphocytes of CTL), a
pro-perty highly regarded in antiparasitic vaccines.
In spite of the many doubts, the field has passed the stage of
interesting observation, to became an increasingly practical
reality. The majority of the viral vaccines tried, have succeeded in
maintaining a sustained antigen production, eliciting both arms of
the immune response. For influenza this is perhaps the best vaccine
ever presented. The overall strategy is to couple a DNA segment
coding for proteins of the capside-core or basic function proteins
to a strong viral promoter, which in turn confers a wide-spectrum
protection; a escape-free immune res-ponse, and a high level of the
antigen expression. The DNA doses are high, ranging from 1 to 100 ug
per shot, and the delivery is now being assayed through nasal sprays
and skin shots (with a Jet-Gun developed at Agrocetus, and licensed
to BioRad). New and better expression vector are being designed, and
the basic mechanisms of DNA uptake, protein expression and
presentation are under intense study, and the field of muscle
immunobiology is widening.
Other viral vaccines are on the list, but the most wanted is AIDS;
four speakers presented advances on HIV vaccines. The newer approach
was to assemble multicistronic constructs covering basic functions
of the virus which in turn confers wide protective spectrum in
monkeys.
Two vaccines against parasitic protozoa were discussed,
Plasmodium falciparum and Leishmania. In the first,
although antigen expression was low, some protection was achieved. A
puzzling fact was the expression of the flanking rather than the
central part of the sporozoite protein. For Leishmania, the
antigen was the surface protease gp 63; the authors got a low level
of expression and protection in experimental animals. These two
examples illustrate the need to think more deeply on non-viral
vaccines: firstly, it is likely that the low expression levels, and
the unexpected expression patterns reflect differences in codon
usage preferences, which are completely different in
Plasmodium and Leishmania, as compared to the
vertebrate host. Secondly, for obvious reasons, it does not seem to
be wise to express whole proteases as antigens.
Few examples of RNA vaccines were discussed, the attractive on using
RNA instead of DNA is its instability, since it would only be
transiently expressed without the risks of integration. These
vaccines are in a vey preliminary stage.
Biosafety issues were discussed extensively: the two main concerns
were the probability of getting insertions of the injected DNA, and
the possibility of raising anti-DNA antibodies. Many speakers
addressed the first issue citing the use of PCR to rule out any
integration into the recipient genome. In my view, even lacking
experimentation, it has been shown that by using retroviral DNA, the
probability of knocking-out a gene, or activating a protooncogene is
very low (Temin 1990). Also, comparing vaccines using whole killed
organisms, a large amount of proteins and DNA is injected, so that a
higher concentration is used, but it is no less true, that within
Leishmania there are highly repeated sequences, such as kDNA
with ten thousand copies per cell.
As to the second issue, DNA is a very poor antigen; even after such
massive injections (100 ug for mice or rats) no anti-DNA antibodies
has been detected in various strains of rats and mice. It is likely
that FDA and other agencies, will deal with DNA-vaccines case by
case, and we may soon see the first human trials.
A very important aspect, included in the agenda but not discussed at
the meeting, was the participation of the Third World. Naked-DNA
vaccines have two very important attributes as "perfect" vaccine for
under-developed countries: thermal stability and inexpensive
production. In a modest laboratory, using standard techniques,
milligrams of DNA can be easily produced, and DNA is very stable. I
will add a third quality, i.e. it is soft-core technology, using
very simple molecular biology protocols and unsophisticated
apparatus. There is a large collection of good antigens already
cloned in Third World laboratories that can readily be used.
A limitation to the technique is patent protection. This is now
being claimed on very wide basis, that is, the concept of
DNA-injection for protection. If granted in this maner, it would
seriously hamper further development.
Finally, a long discussion was made about how the new technique of
vaccination should be called, having in mind the negative public
perception of genetic engineering. Several names were voted on, of
which nucleic acid vaccines was the winner.
Acknowledgements: to Ian Mclure for revising this report.
REFERENCES
Benvenisty N, Reshef L 1986. Direct introduction of genes into rats
and expression of the genes. Proc Natl Acad Sci USA 83:
9551-9555.
Braciale T 1993. Naked DNA and vaccine design. TIM 1:
323-324.
Cohen J 1993. Research News: Naked DNA points way to vaccines.
Science 295: 1691-1692.
Temin H 1990. Overview of biological effects of addition of DNA
molecules to cells. J Med Virol 31: 13-17.
Wolf J, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL
1993. Direct gene transfer into mouse muscle in vivo. Science
259: 1691-1692.
Copyright 1994 Fundacao Oswaldo Cruz - FIOCRUZ
|